Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00606814 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Infinity Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
8
Study locations

NCT00606814 is a Phase 1 study of Solid Tumors that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 60 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00606814, a Phase 1 study of Solid Tumors, has completed, sponsored by Infinity Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
8
Study locations

Study Summary

This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: * the safety profile, * the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and * to recommend a Phase II dose of the combination in patients with solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • DRUG IPI-504, docetaxel

Study Locations (8)

New York

  • Roswell Park Cancer Institute - Buffalo
  • Memorial Sloan-Kettering Cancer Center - New York

Ohio

  • Gabrail Cancer Center - Canton
  • Gabrail Cancer Center - Dover

Arizona

  • TGen Clinical Research in Scottsdale - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • H. Lee Moffitt Cancer Center & Research Institute - Tampa

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2007-12
Est. Completion 2011-12
Phase Phase 1

Sponsor

Infinity Pharmaceuticals

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00606814

The ClinicalTrials.gov registry entry for NCT00606814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (79% lower). The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IPI-504, docetaxel is the first listed.

NCT00606814 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Ohio, Arizona.

Frequently Asked Questions

What is clinical trial NCT00606814 about?

NCT00606814 is a clinical study titled "Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors". This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: * the safety profile, * the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and * to recommend a Phase II dose of the ...

What is the current status of trial NCT00606814?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-12. Estimated completion is 2011-12.

What conditions does trial NCT00606814 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00606814?

The interventions under investigation include: IPI-504, docetaxel (DRUG).

Who is sponsoring clinical trial NCT00606814?

This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00606814 being conducted?

This trial has 8 study locations across Arizona, Connecticut, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.